PMID- 25536600
OWN - NLM
STAT- MEDLINE
DCOM- 20180622
LR  - 20211122
IS  - 1107-0625 (Print)
IS  - 1107-0625 (Linking)
VI  - 19
IP  - 4
DP  - 2014 Oct-Dec
TI  - Clinical significance of Cyclin D1, FGF3 and p21 protein expression in laryngeal 
      squamous cell carcinoma.
PG  - 944-52
AB  - PURPOSE: Laryngeal squamous cell carcinoma (LSCC) represents one of the most 
      common cancers of the head and neck and the search for molecular markers is 
      required for early diagnosis, prognosis and optimal therapy. The purpose of this 
      study was to investigate the clinical significance of Cyclin D1, FGF3, p16 and 
      p21 protein expression in LSCC and laryngeal dysplasia (LD) and to evaluate the 
      associations between their expression levels and clinicopathological parameters 
      of patients with LSCC. METHODS: Immunohistochemistry was employed to detect and 
      quantify the expression levels of Cyclin D1, FGF3, p16 and p21 in the laryngeal 
      tissues of 48 LSCC patients, 32 patients with LD and 28 subjects with healthy 
      laryngeal mucosa (HLM). RESULTS: Significantly higher percentage of LSCC patients 
      had positive Cyclin D1 expression compared with LD patients and HLM subjects 
      (both p<0.01) and positive FGF3 expression than HLM subjects (p<0.05), while no 
      differences in p16 and p21 positive expression were found among studied groups. 
      The levels of Cyclin D1, FGF3 and p16 expression, as evaluated by immunostaining 
      score, were significantly higher in patients with LSCC compared with LD and HLM 
      groups (all p<0.05). Cyclin D1 proved to be highly sensitive and specific marker 
      in differentiating LSCC from LD (sensitivity 81.2%, specificity 83.9%), while 
      high sensitivity (81.2%) and lower specificity (41.4%) was observed in 
      differentiating from HLM. Cyclin D1 and p21 expression levels were associated 
      with regional lymph node metastases (both p<0.05) and Cyclin D1 expression levels 
      significantly correlated with LSCC lymphatic invasion (x(2)=8.862; df=3; 
      ?=0.031). CONCLUSIONS: Cyclin D1, FGF3 and p16 are overexpressed in patients with 
      LSCC. Cyclin D1 is a highly sensitive marker in differentiating LSCC from LD or 
      HLM. Cyclin D1 and p21 expression levels may be useful as predictive markers of 
      metastases in LSCC.
FAU - Jovanovic, Ivan P
AU  - Jovanovic IP
AD  - 1Center for Molecular Medicine and Stem Cell Research, Faculty of Medical 
      Sciences, University of Kragujevac, Serbia.
FAU - Radosavljevic, Gordana D
AU  - Radosavljevic GD
FAU - Simovic-Markovic, Bojana J
AU  - Simovic-Markovic BJ
FAU - Stojanovic, Stevan P
AU  - Stojanovic SP
FAU - Stefanovic, Srdjan M
AU  - Stefanovic SM
FAU - Pejnovic, Nada N
AU  - Pejnovic NN
FAU - Arsenijevic, Nebojsa N
AU  - Arsenijevic NN
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Cyprus
TA  - J BUON
JT  - Journal of B.U.ON. : official journal of the Balkan Union of Oncology
JID - 100883428
RN  - 0 (CCND1 protein, human)
RN  - 0 (CDKN1A protein, human)
RN  - 0 (Cyclin-Dependent Kinase Inhibitor p21)
RN  - 0 (FGF3 protein, human)
RN  - 0 (Fibroblast Growth Factor 3)
RN  - 136601-57-5 (Cyclin D1)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Carcinoma, Squamous Cell/genetics/*metabolism
MH  - Case-Control Studies
MH  - Cyclin D1/*metabolism
MH  - Cyclin-Dependent Kinase Inhibitor p21/*metabolism
MH  - Female
MH  - Fibroblast Growth Factor 3/*metabolism
MH  - Head and Neck Neoplasms
MH  - Humans
MH  - Laryngeal Neoplasms/genetics/*metabolism
MH  - Lymphatic Metastasis
MH  - Male
MH  - Middle Aged
MH  - Prognosis
EDAT- 2014/12/24 06:00
MHDA- 2018/06/23 06:00
CRDT- 2014/12/24 06:00
PHST- 2014/12/24 06:00 [entrez]
PHST- 2014/12/24 06:00 [pubmed]
PHST- 2018/06/23 06:00 [medline]
PST - ppublish
SO  - J BUON. 2014 Oct-Dec;19(4):944-52.